Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Idenix Pharmaceuticals and Janssen Pharmaceuticals have collaborated for the clinical development of direct-acting antiviral (DAA) hepatitis C virus (HCV) combination therapies, retaining all rights to their respective compounds.
Subscribe to our email newsletter
The clinical development program includes Phase II studies evaluating IDX719, simeprevir (TMC435) and TMC647055 for the treatment of HCV after an initial drug-drug interaction study, expected to commence in the first quarter of 2013
Idenix president and chief executive officer Ron Renaud said it looks forward to initiate phase II study in the first quarter of 2013.
"We are very pleased to be working with Janssen and look forward to initiating a phase II study in the first quarter of this year," Renaud added.
"This will allow us to achieve a key goal of ours for 2013, which is to advance the development of IDX719 as part of all-oral HCV combinations in two- and three-drug regimens.
Two-DAA combination of IDX719 and simeprevir along with ribavirin for 12 weeks will initially be assessed under the phase II program in HCV-infected patients new to the treatment.
A three-DAA combination of IDX719, simeprevir and TMC647055/r, with and without ribavirin will be evaluated later.
Idenix will conduct the clinical trials.